PDCD1 and cancer: Studies have suggested that serum cytokine levels, including IL-5 and IFN-γ, could be effective indicators for predicting the clinical efficacy and survival rates in patients with cancer undergoing anti-PD-1 blockade treatment, including those with lung cancer [11].